ATE353665T1 - Glp-2 enthaltende formulierungen - Google Patents

Glp-2 enthaltende formulierungen

Info

Publication number: ATE353665T1
Authority: AT; Austria
Prior art keywords: glp; formulations containing; containing glp; formulations; histidine
Prior art date: 1999-12-30

Application number

AT00988416T

Other languages

English (en)

Inventor

Indu J Isaacs

Original Assignee

Nps Allelix Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-30

Filing date

2000-12-29

Publication date

2007-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10867197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE353665(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-12-29 Application filed by Nps Allelix Corp filed Critical Nps Allelix Corp

2007-03-15 Application granted granted Critical

2007-03-15 Publication of ATE353665T1 publication Critical patent/ATE353665T1/de

Links

101800000221 Glucagon-like peptide 2 Proteins 0.000 title abstract 4
102400000326 Glucagon-like peptide 2 Human genes 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title abstract 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
229930195725 Mannitol Natural products 0.000 abstract 1
230000001747 exhibiting effect Effects 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
229960002885 histidine Drugs 0.000 abstract 1
235000010355 mannitol Nutrition 0.000 abstract 1
239000000594 mannitol Substances 0.000 abstract 1
239000008363 phosphate buffer Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT00988416T 1999-12-30 2000-12-29 Glp-2 enthaltende formulierungen ATE353665T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9930882.7A GB9930882D0 (en)	1999-12-30	1999-12-30	GLP-2 formulations

Publications (1)

Publication Number	Publication Date
ATE353665T1 true ATE353665T1 (de)	2007-03-15

Family

ID=10867197

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00988416T ATE353665T1 (de)	1999-12-30	2000-12-29	Glp-2 enthaltende formulierungen

Country Status (13)

Country	Link
US (1)	US7056886B2 (de)
EP (1)	EP1246639B1 (de)
JP (3)	JP5001498B2 (de)
AT (1)	ATE353665T1 (de)
AU (1)	AU782110B2 (de)
CA (1)	CA2395814C (de)
CY (1)	CY1106558T1 (de)
DE (1)	DE60033437T2 (de)
DK (1)	DK1246639T3 (de)
ES (1)	ES2282161T3 (de)
GB (1)	GB9930882D0 (de)
PT (1)	PT1246639E (de)
WO (1)	WO2001049314A2 (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6057287A (en) *	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20020025933A1 (en) *	1996-08-30	2002-02-28	Knudsen Liselotte Bjerre	GLP-2 derivatives
GB9930882D0 (en) *	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
EP1412384B1 (de)	2001-06-28	2007-12-26	Novo Nordisk A/S	Stabile formulierung von modifiziertem glp-1
EP1572720A4 (de)	2002-05-24	2008-12-24	Nps Allelix Corp	Verfahren zur enzymatischen herstellung von glp-2-(1-33)- und glp-2-(1-34)-peptiden
US7153829B2 (en) *	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
CA2488558C (en) *	2002-06-07	2013-08-20	Dyax Corp.	Prevention and reduction of blood loss
ES2709103T3 (es)	2002-08-28	2019-04-15	Dyax Corp	Métodos para conservar órganos y tejidos
US7411039B2 (en) *	2002-10-14	2008-08-12	Novo Nordisk A/S	GLP-2 compounds, formulations, and uses thereof
CN1812808B (zh) *	2003-06-03	2012-07-04	诺沃挪第克公司	稳定化的药物肽组合物
BRPI0410972C1 (pt) *	2003-06-03	2021-05-25	Novo Nordisk As	método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia
EP1633391B1 (de) *	2003-06-03	2011-10-19	Novo Nordisk A/S	Stabilisierte pharmazeutische peptid zusammensetzungen
KR101159559B1 (ko)	2003-08-05	2012-06-26	노보 노르디스크 에이/에스	신규의 인슐린 유도체
US20060247167A1 (en) *	2003-09-01	2006-11-02	Novo Nordisk A/S	Stable formulations of peptides
WO2005021022A2 (en) *	2003-09-01	2005-03-10	Novo Nordisk A/S	Stable formulations of peptides
EP1685160A1 (de) *	2003-11-10	2006-08-02	Arriva-Prometic Inc.	Trockene rekombinante humane alpha 1-antitrypsin-zusammensetzung
DK3300721T4 (da)	2003-11-20	2025-03-03	Novo Nordisk As	Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
SI1704234T1 (sl)	2003-11-21	2012-08-31	Nps Pharma Inc	Proizvodnja glukagonu podobnih peptidov 2 in analogov
PL1789434T3 (pl) *	2004-08-31	2014-07-31	Novo Nordisk As	Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
US7235530B2 (en) *	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006050244A2 (en)	2004-11-01	2006-05-11	Nps Allelix Corp.	Treatment of short bowel syndrome patients with colon-in-continuity
CN106137952B (zh)	2004-11-12	2020-11-17	诺和诺德公司	促胰岛素肽的稳定制剂
CN100418983C (zh) *	2005-05-11	2008-09-17	中国药科大学	人胰高血糖素相关肽-2类似物
CA2622608C (en)	2005-09-14	2014-08-19	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors for treating diabetes
WO2007033427A1 (en) *	2005-09-23	2007-03-29	Metabolic Pharmaceuticals Limited	Stabilisation of peptides with basic amino acids
US20090074882A1 (en)	2005-12-28	2009-03-19	Novo Nordisk A/S	Insulin compositions and method of making a composition
CA2643693A1 (en) *	2006-03-10	2007-09-20	Dyax Corp.	Formulations for ecallantide
US7879805B2 (en)	2007-06-01	2011-02-01	Acologix, Inc.	High temperature stable peptide formulation
WO2008152106A1 (en)	2007-06-13	2008-12-18	Novo Nordisk A/S	Pharmaceutical formulation comprising an insulin derivative
WO2010042145A1 (en) *	2008-09-19	2010-04-15	Nektar Therapeutics	Polymer conjugates of glp-2-like peptides
CA2738615A1 (en)	2008-10-30	2010-05-06	Novo Nordisk A/S	Treating diabetes melitus using insulin injections with less than daily injection frequency
US8637454B2 (en) *	2009-01-06	2014-01-28	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
WO2011041293A1 (en)	2009-09-30	2011-04-07	Takeda Pharmaceutical Company Limited	Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
US9610329B2 (en)	2009-10-22	2017-04-04	Albireo Pharma, Inc.	Stabilized glucagon solutions
WO2011049713A2 (en) *	2009-10-22	2011-04-28	Biodel Inc.	Stabilized glucagon solutions
EP2314616A1 (de) *	2009-10-23	2011-04-27	Ferring B.V.	GLP-2-Peptid-Agonisten
RS62853B1 (sr)	2010-01-06	2022-02-28	Takeda Pharmaceuticals Co	Proteini koji vezuju kalikrein plazme
SI2531501T1 (sl)	2010-02-03	2014-04-30	Takeda Pharmaceutical Company Limited	Inhibitorji kinaze-1, ki regulirajo signal apoptoze
JP5908478B2 (ja)	2010-08-30	2016-04-26	エヌピーエスファーマシューティカルズインコーポレイテッドＮｐｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	ｈ「Ｇｌｙ２」ＧＬＰ−２の固相合成
JP6049625B2 (ja)	2010-10-27	2016-12-21	ノヴォノルディスクアー／エス	様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
AU2012204202A1 (en)	2011-01-06	2013-07-11	Dyax Corp.	Plasma kallikrein binding proteins
CA2833571A1 (en) *	2011-04-22	2012-10-26	Radius Health, Inc.	Method of drug delivery for pth, pthrp and related peptides
AU2012345768B2 (en)	2011-11-30	2016-05-12	Kindeva Drug Delivery L.P.	Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG10201705097PA (en)	2012-12-21	2017-07-28	Sanofi Sa	Functionalized exendin-4 derivatives
WO2014177623A1 (en)	2013-04-30	2014-11-06	Novo Nordisk A/S	Novel administration regime
EP3080149A1 (de)	2013-12-13	2016-10-19	Sanofi	Duale glp-1-/glucagon-rezeptoragonisten
WO2015086729A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/gip receptor agonists
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
TW201609795A (zh)	2013-12-13	2016-03-16	賽諾菲公司	作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
AU2015235967B2 (en)	2014-03-27	2020-10-22	Takeda Pharmaceutical Company Limited	Compositions and methods for treatment of diabetic macular edema
EP4035664A3 (de)	2014-03-28	2022-11-30	Duke University	Behandlung von krebs unter verwendung von selektiven östrogenrezeptormodulatoren
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
CN104146969A (zh) *	2014-07-31	2014-11-19	浙江美华鼎昌医药科技有限公司	注射用或输注用比伐卢定冻干粉针制剂的制备方法
MX393599B (es)	2015-04-29	2025-03-19	Radius Pharmaceuticals Inc	Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
EP3388089B1 (de) *	2015-12-10	2022-05-18	Menicon Co., Ltd.	Peptidzusammensetzung
CN116077648A (zh)	2015-12-11	2023-05-09	武田药品工业株式会社	血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
EP3296746A1 (de) *	2016-09-20	2018-03-21	Université de Bourgogne	In-vitro-verfahren zur diagnose eines frühstadiums von darmischämie
TWI591177B (zh)	2016-10-27	2017-07-11	中化合成生技股份有限公司	一種胰高血糖素胜肽－２（ｇｌｐ－２）類似物的製備方法
DK3565542T3 (da)	2017-01-05	2024-07-01	Radius Pharmaceuticals Inc	Polymorphic forms of rad1901-2hcl
WO2018142363A1 (en) *	2017-02-06	2018-08-09	Orbicular Pharmaceutical Technologies Private Limited	Ready to use compositions of glp-2 analogues through self-administrable devices
CA3090767A1 (en)	2017-02-27	2018-08-30	Urigen N.A.	Treatment of lower urinary tract epithelium with glucagon like peptide 2
DK3881861T3 (da)	2017-06-16	2024-09-09	Zealand Pharma As	Doseringsregimer for indgivelse af glukagonlignende peptid-2- (GLP-2)-analoger
TWI847306B (zh)	2017-08-24	2024-07-01	丹麥商諾佛儂迪克股份有限公司	Ｇｌｐ-１組成物及其用途
WO2019086559A1 (fr)	2017-10-31	2019-05-09	Adocia	Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3072875B1 (fr) *	2017-10-31	2020-11-06	Adocia	Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3079414B1 (fr) *	2018-03-27	2020-05-01	Adocia	Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
KR102792490B1 (ko)	2018-07-04	2025-04-04	래디어스 파마슈티컬스, 인코포레이티드	Rad1901-2hcl의 다형 형태
EP3628683A1 (de)	2018-09-28	2020-04-01	Zealand Pharma A/S	Formulierungen von analoga des glucagon-like-peptid-2 (glp-2)
EP3628682A1 (de)	2018-09-28	2020-04-01	Zealand Pharma A/S	Formulierungen von analoga des glucagon-like-peptid-2 (glp-2)
JP7422754B2 (ja) *	2018-10-26	2024-01-26	ノヴォノルディスクアー／エス	安定性セマグルチド組成物およびその使用
MX2021009569A (es)	2019-02-12	2021-09-08	Radius Pharmaceuticals Inc	Procesos y compuestos.
CA3138715A1 (en)	2019-06-14	2020-12-17	Zealand Pharma A/S	Pharmaceutical parenteral composition of dual glp1/2 agonist
CN114096269B (zh)	2019-07-12	2024-06-11	诺和诺德股份有限公司	高浓度胰岛素制剂
WO2021119482A1 (en)	2019-12-13	2021-06-17	Progenity, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
MX2022008649A (es)	2020-01-13	2022-09-23	Takeda Pharmaceuticals Co	Inhibidores de calicreina plasmatica y sus usos para tratar episodios de angioedema hereditario pediatrico.
BR112022013795A2 (pt)	2020-02-18	2022-09-13	Novo Nordisk As	Composição farmacêutica líquida, e, kit
EP4154869A4 (de) *	2020-05-22	2025-01-22	Hanmi Pharm. Co., Ltd.	Flüssige formulierung eines langwirkenden glp-2-konjugats
AU2021286563A1 (en)	2020-06-09	2023-01-19	Vectivbio Ag	Manufacture, formulation and dosing of apraglutide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS63307827A (ja) *	1987-06-08	1988-12-15	Kitasato Inst:The	安定化された生ウイルスワクチンおよびその製造法
US5997856A (en) *	1988-10-05	1999-12-07	Chiron Corporation	Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5652216A (en) *	1994-05-26	1997-07-29	Novo Nordisk A/S	Pharmaceutical preparation
PT1516628E (pt) *	1995-07-27	2013-09-24	Genentech Inc	Formulação de proteína liofilizada isotónica estável
US5912229A (en) *	1996-03-01	1999-06-15	Novo Nordisk Als	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
EP1231219B1 (de)	1996-04-12	2010-08-25	1149336 Ontario Inc.	Dem Glukagon ähnliches Peptid-2
TW518219B (en) *	1996-04-26	2003-01-21	Chugai Pharmaceutical Co Ltd	Erythropoietin solution preparation
US5994500A (en) *	1996-07-19	1999-11-30	1149336 Ontario Inc.	Antagonists of intestinotrophic GLP-2 peptides
US5952301A (en) *	1996-12-10	1999-09-14	1149336 Ontario Inc.	Compositions and methods for enhancing intestinal function
WO1998025955A2 (en) *	1996-12-13	1998-06-18	Allelix Biopharmaceuticals Inc.	Cloned glucagon-like peptide-2 receptors
WO1999043361A1 (en) *	1998-02-27	1999-09-02	Novo Nordisk A/S	Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
GB9930882D0 (en) *	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations

1999
- 1999-12-30 GB GBGB9930882.7A patent/GB9930882D0/en not_active Ceased
2000
- 2000-12-29 ES ES00988416T patent/ES2282161T3/es not_active Expired - Lifetime
- 2000-12-29 CA CA2395814A patent/CA2395814C/en not_active Expired - Lifetime
- 2000-12-29 AU AU24626/01A patent/AU782110B2/en not_active Expired
- 2000-12-29 DE DE60033437T patent/DE60033437T2/de not_active Expired - Lifetime
- 2000-12-29 JP JP2001549681A patent/JP5001498B2/ja not_active Expired - Lifetime
- 2000-12-29 EP EP00988416A patent/EP1246639B1/de not_active Expired - Lifetime
- 2000-12-29 PT PT00988416T patent/PT1246639E/pt unknown
- 2000-12-29 DK DK00988416T patent/DK1246639T3/da active
- 2000-12-29 US US09/750,022 patent/US7056886B2/en not_active Expired - Lifetime
- 2000-12-29 AT AT00988416T patent/ATE353665T1/de active
- 2000-12-29 WO PCT/US2000/035512 patent/WO2001049314A2/en not_active Ceased
2007
- 2007-05-04 CY CY20071100588T patent/CY1106558T1/el unknown
2012
- 2012-02-10 JP JP2012027323A patent/JP5604463B2/ja not_active Expired - Lifetime
2014
- 2014-05-07 JP JP2014095701A patent/JP5934739B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES2282161T3 (es)	2007-10-16
CY1106558T1 (el)	2012-01-25
AU2462601A (en)	2001-07-16
EP1246639B1 (de)	2007-02-14
CA2395814A1 (en)	2001-07-12
JP2003519195A (ja)	2003-06-17
JP2012116861A (ja)	2012-06-21
US7056886B2 (en)	2006-06-06
EP1246639A2 (de)	2002-10-09
CA2395814C (en)	2011-09-20
PT1246639E (pt)	2007-05-31
GB9930882D0 (en)	2000-02-23
JP5604463B2 (ja)	2014-10-08
US20010027180A1 (en)	2001-10-04
AU782110B2 (en)	2005-07-07
JP5934739B2 (ja)	2016-06-15
DK1246639T3 (da)	2007-06-11
JP2014159463A (ja)	2014-09-04
JP5001498B2 (ja)	2012-08-15
WO2001049314A3 (en)	2002-01-03
DE60033437D1 (de)	2007-03-29
DE60033437T2 (de)	2007-11-29
WO2001049314A2 (en)	2001-07-12

Legal Events

Date

Code

Title

Description

2007-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1246639

Country of ref document: EP

Publication	Publication Date	Title
ATE353665T1 (de)	2007-03-15	Glp-2 enthaltende formulierungen
ATE244015T1 (de)	2003-07-15	Formulierungen fuer faktor ix
EA200100519A1 (ru)	2002-02-28	Композиции на основе тонкоизмельченного эплеренона
ATE270557T1 (de)	2004-07-15	Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
BR0109943A (pt)	2003-05-27	Composições farmacêuticas
DK1086706T3 (da)	2004-03-08	Stabiliserede sammensætninger indeholdende nootropiske lægemidler
CO5700784A2 (es)	2006-11-30	Polipeptidos de virus de papiloma humano y composiciones in- munogenas
ZA981031B (en)	1998-08-11	Methods for producing dired storage-stable platelets and compositions obtained thereby
PT921812E (pt)	2002-04-29	Preparacoes de insulina contendo um halogenuro
MY122262A (en)	2006-04-29	Lh-rh peptide analogues their uses and pharmaceutical compositions containing them
DK0655917T3 (da)	2004-07-26	Krystallinske amifostin-præparater og fremgangsmåder til fremstilling og anvendelse af samme
BRPI9715334B8 (pt)	2021-05-25	agentes estrogênicos e composição farmacêutica compreendendo os mesmos.
DE69417252D1 (de)	1999-04-22	Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
DE69508837D1 (de)	1999-05-12	Protein enthaltende stabilisierte Formulierung und Dosierungskit
ATE218581T1 (de)	2002-06-15	Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
HUP0100669A2 (hu)	2001-08-28	Szerin proteázokat gátló peptidszármazékok és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
ATE486587T1 (de)	2010-11-15	Formulierungen zur oralen verabreichung von wirkstoffen
BR0011030A (pt)	2002-02-26	Composições de cicloporina substancialmente livre de óleo
BG99177A (bg)	1995-07-28	Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
TR199902034T2 (xx)	1999-11-22	Haricen kullan�m i�in nimes�lid jel sistemleri.
BG66082B1 (bg)	2011-03-31	Стабилизирани интерферонови състави
BR0312889A (pt)	2005-06-14	Polipeptìdeo t20 peguilado
AR020106A1 (es)	2002-04-10	Variantes estabilizadas del inhibidor de la subtilisina de streptomyces, gen mutante que la codifica y composicion que comprende dicha variante
DK201879A (da)	1979-11-18	Fremgangsmaade til stabilisering af prostacyclinforbindelser
ATE371737T1 (de)	2007-09-15	Proteaseresistente flint-analoge